Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAXV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics Chief Financial Officer Ajim Tamboli reported equity compensation awards in the form of stock options and restricted stock units. He received employee stock options to buy 41,234, 41,233 and 41,233 shares of common stock at exercise prices of $19.00, $18.87 and $17.00 per share, each expiring in 2036. He also received 45,700 restricted stock units, each representing the right to receive one share for no cash payment. The options vest 25% on April 20, 2027 and then monthly, while the RSUs vest 25% on the same date and then in equal annual installments, in each case contingent on continued service.
First Tracks Biotherapeutics, Inc. filed an initial Form 3 for Chief Financial Officer Ajim Tamboli. A Form 3 is used to disclose an insider’s starting ownership when they first become a reporting person. In this filing data, no transactions or specific share holdings are listed.
First Tracks Biotherapeutics ownership disclosure: EcoR1 Capital, LLC and affiliated reporting persons state beneficial ownership of Common Stock following a distribution received April 20, 2026. EcoR1 and Oleg Nodelman each report 3,174,519 shares (9.1% of the class); EcoR1 Capital Fund Qualified, L.P. reports 2,981,908 shares (8.5%). The reporting persons received 7,880,094 shares in the distribution and sold 4,705,575 shares in a private placement on the distribution date. Shares outstanding are listed as 34,892,381 as of April 20, 2026.
First Tracks Biotherapeutics, Inc. insider filing shows funds advised by EcoR1 Capital, LLC sold 4,705,575 shares of Common Stock at $13.8134 per share in a transaction coded as an open-market or private sale.
According to the disclosure, the shares are held directly by EcoR1-managed funds for the benefit of their investors, with EcoR1 and its control person Oleg Nodelman only indirectly deemed beneficial owners to the extent of their pecuniary interests. A footnote states the funds sold these shares in a private placement described in a separate Form 8-K.
The filing notes that EcoR1 Capital Fund Qualified L.P. sold 4,420,064 of the shares in this transaction and, after the sale, holds 2,981,908 First Tracks Biotherapeutics common shares. Overall indirect holdings reported for EcoR1 after the transaction total 3,174,519 shares, indicating the funds retain a sizable, but reduced, position.
EcoR1 Capital, LLC filed an initial Form 3 for First Tracks Biotherapeutics, Inc., reporting indirect beneficial ownership of 7,880,094 shares of Common Stock held by its investment funds. A key fund, EcoR1 Capital Fund Qualified L.P., beneficially owns 7,401,972 shares. These shares were received by the funds through a pro rata distribution of First Tracks Common Stock by AnaptysBio, Inc. on April 20, 2026, which the filing states qualified for the exemption provided by Rule 16a-9 under the Exchange Act.
First Tracks Biotherapeutics, Inc. Chief Business Officer Benjamin Stone has filed a Form 3 showing his equity holdings in the company. He directly holds 17,262 shares of common stock, including shares received in the spin-off of First Tracks from AnaptysBio.
Stone also holds performance stock units covering 50,000 underlying shares of common stock that vest based on performance metrics, with potential vesting dates in July 2025, July 2026 and July 2028. In addition, he has multiple tranches of restricted stock units, including awards tied to annual 25% vesting schedules beginning in January 2024, January 2025, January 2026 and January 2027.
The filing further lists several employee stock options with exercise prices ranging from $3.97 to $11.75 per share and expirations between 2032 and 2036, reflecting a mix of fully vested and time-vested option grants that align with his ongoing service to the company.
Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. Chief Medical Officer Paul F. Lizzul reported equity awards and holdings tied to the spin-off from AnaptysBio, Inc. On the common stock line, he is shown holding 42,669 shares directly.
Footnotes explain that these shares, as well as stock options and restricted stock units, were received or adjusted in connection with a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks. Multiple RSU awards and stock options over First Tracks common stock were listed, with future vesting over several years, reflecting compensation and spin-off adjustments rather than open-market trading.
First Tracks Biotherapeutics director Ware J. Anthony reported equity awards and holdings following the company’s spin-off from AnaptysBio. He holds 9,630 shares of common stock received in the pro rata distribution tied to the Separation and Distribution Agreement dated April 20, 2026.
He also acquired multiple stock options and restricted stock units that were adjusted from prior AnaptysBio awards. These include RSUs for 4,000 and 6,030 shares of common stock, each RSU representing one share upon settlement at no cost, plus several fully vested and time‑vested stock options with exercise prices between $3.97 and $28.03 per share and expirations between 2027 and 2036. The RSUs are scheduled to vest in full at the company’s 2026 and 2027 annual shareholder meetings, subject to continued service.
Schmid John P. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics director John P. Schmid reported equity awards and spin-off related holdings. He directly holds 31,622 shares of common stock received in connection with the spin-off from AnaptysBio. Schmid also holds restricted stock units and multiple stock option grants that provide additional exposure to First Tracks shares.
He was granted 4,000 RSUs vesting in full on the company’s 2026 annual shareholder meeting and 6,030 RSUs vesting in full at the 2027 meeting, each settling into one share of common stock per unit for no cash cost. Footnotes state that his stock options and RSUs were adjusted under a Separation and Distribution Agreement so that awards now cover both First Tracks and AnaptysBio. One option grant is fully vested, while another vests in 12 equal monthly installments beginning February 6, 2026.
Orwin John A reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics director John A. Orwin reported new equity awards tied to the spin-off from AnaptysBio. He holds 10,665 shares of common stock received in a pro rata distribution at separation.
On April 20, 2026, he was credited with three restricted stock unit blocks of 6,000, 6,030 and 1,300 RSUs, each representing one common share upon settlement for no cash consideration. These RSUs include tranches vesting in thirds on September 15, 2024, 2025 and 2026, plus separate grants vesting 100% on the company’s 2026 and 2027 annual shareholder meeting dates, subject to continued service.
He also received or had adjusted stock options over common shares, including 8,250 options at $11.75 per share that are fully vested, and additional options for 16,510 shares at $3.97, 16,510 at $5.67, and 10,600 and 3,311 at $5.22 per share, with expirations between 2033 and 2036 and vesting schedules commencing monthly from February 6, 2026. Footnotes state these option and RSU positions were adjusted so that AnaptysBio awards became awards in both AnaptysBio and First Tracks under their Separation and Distribution Agreement.